Biotronik launches a new series of Ilivia CRT devices


Biotronik has announced the launch of a new series of cardiac resynchronisation therapy (CRT) devices with several functionalities that allow physicians to offer an all-inclusive and individualised solution for optimised CRT.

“Biotronik’s new CRT-Ds are equipped with numerous features that address physicians’ concerns about cardiac resynchronisation therapy,” says Christof Kolb, German Heart Center, Munich, Germany. “The energy-efficient MultiPole Pacing has great potential to increase patients’ response to CRT and to sustain this in the long term.”

Biotronik states that the Ilivia series of CRT-Ds is specifically designed to address the 30 to 40% non-response rate to CRT without causing disproportionate additional battery drain. The system features MultiPole Pacing (MPP) for sequential or simultaneous pacing in the left ventricle (LV) that is individually programmable for an increased response rate. To further improve therapy success, this is complemented by a diverse portfolio of LV leads for different patient anatomies and target veins, including a newly launched Sentus QP lead with alternative pole-spacing for short to medium veins.

The Ilivia CRT-D series also offers ProMRI and is equipped with Biotronik’s award-winning MRI AutoDetect feature, which enables the device to automatically recognise an MRI environment within a programmable time window, and switch itself to and from MRI mode. This simplifies the process of MRI scans for both patients and physicians and decreases the duration of reduced therapy, offering increased patient safety.